United Therapeutics has settled litigation that may impact its valuation.
United Therapeutics Corporation has settled a legal dispute involving a payment of $380.7 million, raising questions about whether the company is undervalued. The stock closed at US$540.35, down 0.62% for the day and 0.91% for the week. However, it has appreciated by 8.72% year-to-date, showing a positive trend despite recent fluctuations.
Advertisement
United Therapeutics Corporation
UTHR.US
UTHR.US
United Therapeutics Corporation
WealthAwesomeMarket cap
$23.16B
P/E
19.4x
52W high
$609.35
52W low
$409.07
1W change
-0.91%
Beta
0.49
Analyst Price Targets
Based on 15 analysts covering UTHR · as of Oct 15, 2026
Wall Street analysts forecast UTHR stock price to rise 20.6% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
C$651.15
+20.6% Upside
Previously C$651.86 on Oct 13, 2026
Current Price
C$540.03
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on UTHR's historical volatility
30-Day Vol
48.0%
Annualized
90-Day Vol
32.7%
Annualized
Trend (90d)
+3.3%
Annualized drift
90d Mean
C$546.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$542.14 | C$459.42 – C$639.76 |
| 60 trading days | C$544.26 | C$430.65 – C$687.86 |
| 90 trading days | C$546.39 | C$410.17 – C$727.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should assess how the legal settlement affects United Therapeutics' financial health and market position.
Latest Close: US$540.35
United Therapeutics has a market cap of approximately US$23.16 billion and a P/E ratio of 19.36. The stock is trading above its 50-day moving average of US$513.78 and its 200-day moving average of US$526.46.
Bull case
The settlement could allow United Therapeutics to refocus on growth opportunities, which may boost investor sentiment and improve company performance.
Bear case
The large settlement cost might strain cash flow and raise concerns about future financial commitments, potentially shaking market confidence.
Settlement Overview
Advertisement
United Therapeutics has settled a legal dispute involving a payment of $380.7 million, which is expected to limit the label of its drug, Yutrepia. This settlement may provide clarity for the company as it moves forward. With the stock currently priced at US$540.35, it is positioned at 66% of its 52-week range of US$409.07 to US$609.35. This development could enable the company to concentrate on its core business without the burden of ongoing litigation.
Stock Performance Insights
As of the latest close, United Therapeutics stock is priced at US$540.35, reflecting a 1-day decline of 0.62%. The trading volume was 3,099 shares, which is 0.86 times the 20-day average volume of 1,007,036 shares, indicating reduced investor activity. Over the past month, the stock has increased by 7.43%, suggesting some resilience despite the recent legal developments.
Future Considerations
Looking ahead, investors will closely monitor how the settlement impacts United Therapeutics' competitive positioning and financial health. Analysts have set an average target price of US$651.15, indicating a potential upside of 20.5% from the current price. The company's strong profit margin of 41.6% and return on equity of 19.3% may continue to attract investor interest as it navigates this new phase post-settlement.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
